Robust spike antibody responses, increased reactogenicity in seropositive individuals after single dose of SARS-CoV-2 mRNA vax

 Florian Krammer1$, Komal Srivastava1 , the PARIS team1*, and Viviana Simon1,2,3

 doi: https://doi.org/10.1101/2021.01.29.21250653

Abstract 

An important question is arising as COVID-19 vaccines are getting rolled out: Should individuals who already had a SARS-CoV-2 infection receive one or two shots of the currently authorized mRNA vaccines. In this short report, we show that the antibody response to the first vaccine dose in individuals with pre-existing immunity is equal to or even exceeds the titers found in naïve individuals after the second dose. We also show that the reactogenicity is significantly higher in individuals who have been infected with SARS-CoV-2 in the past. Changing the policy to give these individuals only one dose of vaccine would not negatively impact on their antibody titers, spare them from unnecessary pain and free up many urgently needed vaccine doses.

https://www.medrxiv.org/content/10.1101/2021.01.29.21250653v1.full.pdf